Our top pick for
Y-mAbs Therapeutics, Inc is a biotechnology business based in the US. Y-mAbs Therapeutics shares (YMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Y-mAbs Therapeutics employs 65 staff and has a market cap (total outstanding shares value) of USD$2 billion.
|Latest market close||USD$49.51|
|52-week range||USD$14.16 - USD$55.22|
|50-day moving average||USD$49.7162|
|200-day moving average||USD$43.2619|
|Wall St. target price||USD$59|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.83|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-06)||N/A|
|1 month (2020-12-13)||N/A|
|3 months (2020-10-13)||N/A|
|6 months (2020-07-13)||N/A|
|1 year (2020-01-13)||N/A|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-62.58%|
|Return on equity TTM||-121.06%|
|Market capitalisation||USD$2 billion|
TTM: trailing 12 months
There are currently 3.5 million Y-mAbs Therapeutics shares held short by investors – that's known as Y-mAbs Therapeutics's "short interest". This figure is 1.6% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting Y-mAbs Therapeutics shares can be evaluated.
Y-mAbs Therapeutics's "short interest ratio" (SIR) is the quantity of Y-mAbs Therapeutics shares currently shorted divided by the average quantity of Y-mAbs Therapeutics shares traded daily (recently around 242379.05686546). Y-mAbs Therapeutics's SIR currently stands at 14.42. In other words for every 100,000 Y-mAbs Therapeutics shares traded daily on the market, roughly 14420 shares are currently held short.
However Y-mAbs Therapeutics's short interest can also be evaluated against the total number of Y-mAbs Therapeutics shares, or, against the total number of tradable Y-mAbs Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Y-mAbs Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Y-mAbs Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1154% of the tradable shares (for every 100,000 tradable Y-mAbs Therapeutics shares, roughly 115 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Y-mAbs Therapeutics.
Find out more about how you can short Y-mAbs Therapeutics stock.
We're not expecting Y-mAbs Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Y-mAbs Therapeutics's shares have ranged in value from as little as $14.16 up to $55.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Y-mAbs Therapeutics's is 1.3312. This would suggest that Y-mAbs Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.